Literature DB >> 21219976

Immune responses induced by heat killed Saccharomyces cerevisiae: a vaccine against fungal infection.

Min Liu1, Karl V Clemons, Marty Bigos, Izabela Medovarska, Elmer Brummer, David A Stevens.   

Abstract

Heat-killed Saccharomyces cerevisiae (HKY) used as a vaccine protects mice against systemic aspergillosis and coccidioidomycosis. Little is known about the immune response induced by HKY vaccination, consequently our goal was to do an analysis of HKY-induced immune responses involved in protection. BALB/c mice were vaccinated subcutaneously 3 times with HKY, a protective reagent, and bronchoalveolar lavage fluid, spleen, lymph nodes, and serum collected 2-5 weeks later. Cultured spleen or lymph node cells were stimulated with HKY. Proliferation of HKY-stimulated spleen or lymph node cells was tested by Alamar Blue reduction and flow cytometry. Cytokines from lymphocyte supernatants and antibody to glycans in serum collected from HKY-vaccinated mice were measured by ELISA. The results show that HKY promoted spleen cell and lymph node cell proliferation from HKY-vaccinated mice but not from PBS-vaccinated control mice (all P<0.05). Cytokine measurement showed HKY significantly promoted IFNγ, IL-6 and IL-17A production by spleen cells and lymph node cells (all P<0.05 and P<0.01, respectively). Cytokine production by HKY-stimulated cells from PBS-vaccinated mice was lower than those from HKY-vaccinated (P<0.05). Cytokines in BAL from HKY-vaccinated were higher, 1.7-fold for IFNγ and 2.1-fold for TNFα, than in BAL from PBS-vaccinated. Flow cytometry of lymphocytes from HKY-vaccinated showed 52% of CD3(+) or 56% of CD8(+) cells exhibited cell division after stimulation with HKY, compared to non-stimulated controls (26 or 23%, respectively) or HKY-stimulated cells from PBS-vaccinated (31 or 34%). HKY also induced antibody against Saccharomyces glucan and mannan with titers 4- or 2-fold, respectively, above that in unvaccinated. Taken together, the results suggested that HKY vaccination induces significant and specific Th1 type cellular immune responses and antibodies to glucan and mannan.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21219976      PMCID: PMC5508752          DOI: 10.1016/j.vaccine.2010.12.119

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  45 in total

1.  Cutting edge: roles of Toll-like receptor 4 and IL-23 in IL-17 expression in response to Klebsiella pneumoniae infection.

Authors:  Kyle I Happel; Mingquan Zheng; Erana Young; Lee J Quinton; Euan Lockhart; Alistair J Ramsay; Judd E Shellito; Jill R Schurr; Gregory J Bagby; Steve Nelson; Jay K Kolls
Journal:  J Immunol       Date:  2003-05-01       Impact factor: 5.422

2.  Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells.

Authors:  Estelle Bettelli; Yijun Carrier; Wenda Gao; Thomas Korn; Terry B Strom; Mohamed Oukka; Howard L Weiner; Vijay K Kuchroo
Journal:  Nature       Date:  2006-04-30       Impact factor: 49.962

3.  Vaccinations with recombinant variants of Aspergillus fumigatus allergen Asp f 3 protect mice against invasive aspergillosis.

Authors:  James I Ito; Joseph M Lyons; Teresa B Hong; Daniel Tamae; Yi-Kuang Liu; Sharon P Wilczynski; Markus Kalkum
Journal:  Infect Immun       Date:  2006-09       Impact factor: 3.441

4.  CD4+ T cell-independent DNA vaccination against opportunistic infections.

Authors:  Mingquan Zheng; Alistair J Ramsay; Myles B Robichaux; Corrine Kliment; Christopher Crowe; Rekha R Rapaka; Chad Steele; Florencia McAllister; Judd E Shellito; Luis Marrero; Paul Schwarzenberger; Qiu Zhong; Jay K Kolls
Journal:  J Clin Invest       Date:  2005-11-23       Impact factor: 14.808

5.  A microculture system for the measurement of antigen-induced murine lymphocyte proliferation: advantages of 5% horse serum and 5 X 10(-5) M mercaptoethanol.

Authors:  E Brummer; T W Vris; H S Lawrence
Journal:  J Immunol Methods       Date:  1977       Impact factor: 2.303

6.  Protection against candidiasis by an immunoglobulin G3 (IgG3) monoclonal antibody specific for the same mannotriose as an IgM protective antibody.

Authors:  Y Han; M H Riesselman; J E Cutler
Journal:  Infect Immun       Date:  2000-03       Impact factor: 3.441

7.  Protein expression profiling of Coccidioides posadasii by two-dimensional differential in-gel electrophoresis and evaluation of a newly recognized peroxisomal matrix protein as a recombinant vaccine candidate.

Authors:  Kris I Orsborn; Lisa F Shubitz; Tao Peng; Ellen M Kellner; Marc J Orbach; Paul A Haynes; John N Galgiani
Journal:  Infect Immun       Date:  2006-03       Impact factor: 3.441

8.  Murine pulmonary macrophages: evaluation of lung lavage fluids, miniaturized monolayers, and candidacidal activity.

Authors:  A M Sugar; E Brummer; D A Stevens
Journal:  Am Rev Respir Dis       Date:  1983-01

Review 9.  Th17 cells in immunity and autoimmunity.

Authors:  M Oukka
Journal:  Ann Rheum Dis       Date:  2008-12       Impact factor: 19.103

10.  Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defense.

Authors:  P Ye; F H Rodriguez; S Kanaly; K L Stocking; J Schurr; P Schwarzenberger; P Oliver; W Huang; P Zhang; J Zhang; J E Shellito; G J Bagby; S Nelson; K Charrier; J J Peschon; J K Kolls
Journal:  J Exp Med       Date:  2001-08-20       Impact factor: 14.307

View more
  17 in total

Review 1.  Fungal vaccines and immunotherapeutics.

Authors:  Evelyn Santos; Stuart M Levitz
Journal:  Cold Spring Harb Perspect Med       Date:  2014-11-03       Impact factor: 6.915

Review 2.  Universal fungal vaccines: could there be light at the end of the tunnel?

Authors:  Mawieh Hamad
Journal:  Hum Vaccin Immunother       Date:  2012-08-24       Impact factor: 3.452

3.  Killed Saccharomyces cerevisiae protects against lethal challenge of Cryptococcus grubii.

Authors:  Tanya Majumder; Min Liu; Vicky Chen; Marife Martinez; Danielle Alvarado; Karl V Clemons; David A Stevens
Journal:  Mycopathologia       Date:  2014-08-15       Impact factor: 2.574

4.  Saccharomyces cerevisiae expressing Gp43 protects mice against Paracoccidioides brasiliensis infection.

Authors:  Mariana Aprigio Assis-Marques; Aline Ferreira Oliveira; Luciana Pereira Ruas; Thaila Fernanda dos Reis; Maria Cristina Roque-Barreira; Paulo Sergio Rodrigues Coelho
Journal:  PLoS One       Date:  2015-03-19       Impact factor: 3.240

5.  Heat-killed yeast protects diabetic ketoacidotic-steroid treated mice from pulmonary mucormycosis.

Authors:  Guanpingsheng Luo; Teclegiorgis Gebremariam; Karl V Clemons; David A Stevens; Ashraf S Ibrahim
Journal:  Vaccine       Date:  2014-05-06       Impact factor: 3.641

6.  Progress Toward a Human Vaccine Against Coccidioidomycosis.

Authors:  Garry T Cole; Brady J Hurtgen; Chiung-Yu Hung
Journal:  Curr Fungal Infect Rep       Date:  2012-12-01

Review 7.  Development of vaccines for Candida albicans: fighting a skilled transformer.

Authors:  Antonio Cassone
Journal:  Nat Rev Microbiol       Date:  2013-12       Impact factor: 60.633

Review 8.  Fungal cell wall vaccines: an update.

Authors:  John E Edwards
Journal:  J Med Microbiol       Date:  2012-01-19       Impact factor: 2.472

9.  Whole Pichia pastoris yeast expressing measles virus nucleoprotein as a production and delivery system to multimerize Plasmodium antigens.

Authors:  Daria Jacob; Claude Ruffie; Myriam Dubois; Chantal Combredet; Rogerio Amino; Pauline Formaglio; Olivier Gorgette; Gérard Pehau-Arnaudet; Charline Guery; Odile Puijalon; Jean-Christophe Barale; Robert Ménard; Frédéric Tangy; Monica Sala
Journal:  PLoS One       Date:  2014-01-27       Impact factor: 3.240

Review 10.  New insights on the development of fungal vaccines: from immunity to recent challenges.

Authors:  Natasha P Medici; Maurizio Del Poeta
Journal:  Mem Inst Oswaldo Cruz       Date:  2015-11-24       Impact factor: 2.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.